GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Komipharm International Co Ltd (XKRX:041960) » Definitions » Debt-to-Asset

Komipharm International Co (XKRX:041960) Debt-to-Asset : 0.36 (As of Dec. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Komipharm International Co Debt-to-Asset?

Komipharm International Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩34,733 Mil. Komipharm International Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩9,106 Mil. Komipharm International Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was ₩122,767 Mil. Komipharm International Co's debt to asset for the quarter that ended in Dec. 2024 was 0.36.


Komipharm International Co Debt-to-Asset Historical Data

The historical data trend for Komipharm International Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Komipharm International Co Debt-to-Asset Chart

Komipharm International Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.29 0.29 0.34 0.38 0.36

Komipharm International Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.38 0.35 0.36 0.33 0.36

Competitive Comparison of Komipharm International Co's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Komipharm International Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Komipharm International Co's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Komipharm International Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Komipharm International Co's Debt-to-Asset falls into.


;
;

Komipharm International Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Komipharm International Co's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(34733.466 + 9105.701) / 122766.616
=0.36

Komipharm International Co's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(34733.466 + 9105.701) / 122766.616
=0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Komipharm International Co  (XKRX:041960) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Komipharm International Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Komipharm International Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Komipharm International Co Business Description

Traded in Other Exchanges
N/A
Address
1236-6 Jungwang-Dong, Sihung, Gyeonggi, KOR, 429-450
Komipharm International Co Ltd is involved in the healthcare sector based in Korea. Its core business includes development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The company produces its products under two divisions: veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle. The other division is made up of veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis and swine erysipelas.

Komipharm International Co Headlines

No Headlines